Please find attached the Investor Presentation on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026

July 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400051 Mumbai- 400001 (SYMBOL: THYROCARE) (SCRIP CODE: 539871) Sub: Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026 Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir(s)/ Madam, We are enclosing - a copy of the Investor presentation to be made at the earnings conference call for analysts and investors, to be held today, i.e. July 23, 2026, at 06:00 P.M. (IST) on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026. The same is also being made available on the Company’s website https://investor.thyrocare.com/ We request you to please take the same on record. Yours Faithfully, For Thyrocare Technologies Limited, Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a FromRoutine Remarkable: The Next Frontier of Diagnostics Q1 FY27 Earnings Presentation Safe Harbour Statement This presentation has been prepared by Thyrocare Technologies Limited ("Thyrocare"/"TTL"/"Company") for general information purposes only. While reasonable care has been taken in preparing the information, the Company makes no representation or warranty, express or implied, as to its accuracy, completeness or reliability, and accepts no liability for any lossarisingfromtheuseoforrelianceonthispresentation. This presentation contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will,""anticipates,""believes,""intends,""projects,""estimates"orotherwordsofsimilarmeaning. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Actual results may differ materially due to various risks, uncertainties and other factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of newinformation,futureeventsorotherwise. Contents Particulars Pg no. Who we are 04 Our Journey 06 Q1 FY27 Performance Snapshot 07 Other Highlights of Q1 FY27 08 Q1 FY27 Performance - Detailed 14 Going forward –Key Pillars of Growth 23 Thyrocare - Making good quality diagnostics affordable to all since 1996 Global in our reach, To make good quality excellence in our experience diagnostics affordable to all 44 1,375+ 97% 11,700+ Pan India Home Total Labs Comprehensive Samples Quarterly (Incl 1 Test Menu Processed at Active Service International NABL Labs Franchisee Lab in Tanzania) Trusted Brands PAN India presence with network of 44 labs (incl. 1 international lab) which are 100% - NABL Accredited* Region-wise Region-wise India Lab count India Pathology revenue mix%^ 11 24% 21% East West North 24% 31% South 02 CPL 02 ZPL Central Processing Labs Zonal Processing Labs 22 RPL 06 SPL Regional Processing Labs Satellite Processing Labs 07 Hybrid 04 Acquired Hybrid Labs Acquired Labs +1 International lab –Tanzania * Excluding hybrid labs & Tanzania lab 5 ^ Basis Lab Processing Improvement across quality, reliability and reach over last 5 years Active Lab Network Test Menu Franchisee E 44 Labs 11,700+ 1,375+ 17 Labs 3,600+ 275+ FY2021 Q1FY27 FY2021 Q1FY27 FY2021 Q1FY27 (Inc.1 international lab in Tanzania) T Lab Phlebo Top of the line L Turnaround I On-time Arrival lab equipment time I L ~99% 3.37 hours ~INR 250 Crores R (60 Min slot adherence) Capital Expenditure over past 5 Years Y NABL Samples Pathologists Complaints per Processed I L Million tests 100+ U <10 97% Q FY2021 Q1FY27 Samples Processed at NABL Labs Q1 FY27 - Delivered 24% YoY revenue and 34% YoY PAT growth with highest quality standards Financial Parameters Operational Parameters Quality Parameters 240 Cr (+24% YoY) 11,730 97% Consolidated Revenue Quarterly Active Franchisees Samples Processed in NABL Labs 226 Cr (+26% YoY) 5.4 Mn (+17% YoY) 55.2 Mn* (+28% YoY) Standalone Revenue Patients Tests Conducted 143 Cr (+27% YoY) 1,375 tests 3.1 (24% Down YoY) Franchisee Revenue Test Menu Offerings Complaints Per Mn Tests New Technology Addition 71 Cr (+26% YoY) • Gut Microbiome Partnership Revenue • Whole Exome sequencing Revenue: +24% YoY EBITDA: +34% YoY PAT: +34% YoY * Definition of test conducted revised from Q1 FY27 to exclude calculated parameters. Restated numbers from previous quarters: 7 -FY26 Q1 –43.1 Mn, Q2 –48.4 Mn, Q3 –44.5 Mn, Q4 –52.7 Mn -FY25 Q1 –34.7 Mn, Q2 –39.9 Mn, Q3 –36.6 Mn, Q4 –41.0 Mn Expanding capabilities through new service launches and lab additions Brand Elevation through national recognition Thyrocare was honored with the "India's Most Trusted At Financial Express Healthcare Awards 2026, Thyrocare Customer-Focused Diagnostic Brand – 2026" award at the was recognised with top honorsin two categories: Pride of Healthcare Excellence Awards & Summit 2026 • Diagnostic Chain of the Year • Pathology Lab Chain of the year Launch of new Laboratories Launched a new Regional Processing Laboratory in Muzaffarpur and Hybrid labs in Prayagraj and Kurnool. These facilities will strengthen our testing network and improve turnaroundtimes in nearby catchment areas Strengthening our relationships with channel partners (1/2) In Q1 FY27, Thyrocare conducted franchisee meetings, capturing feedback from franchisees across those locations. These insightswere used to strengthen processes, service delivery, and overall quality outcome Strengthening our relationships with channel partners (2/2) Strengthening our relationships with Doctors In Q1 FY27, We conducted 23 Doctor meetings, capturing feedback from ~100 doctors across those locations. These insightswere used to strengthen processes, service delivery, and overall quality outcome Financial Performance Q1 FY27 +24% +26% YoY TTL YoY Pathology Consolidated Revenue Revenue +34% 32% (+226bps) YoY EBITDA EBITDA Margin +34% 21% (+155bps) YoY PAT PAT Margin 24% YoY revenue growth in overall business and 34% YoY growth in EBITDA in Q1 FY27 Consolidated Revenue (INR Cr) EBITDA (INR Cr) +24% +34% 216.5 223.9 240.0 75.1 77.3 193.0 195.5 71.5 57.8 57.6 226.5 179.0 202.3 183.1 211.5 68.6 72.2 74.7 55.6 56.7 14.1 14.2 12.4 12.5 13.5 2.2 2.9 0.9 2.9 2.7 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 EBITDA% 30% 33% 29% 34% 32% YoY Growth% YoY Growth% Pathology + 34% Pathology +27% Radiology + 23% Radiology -4% Radiology Business consists of Nuclear healthcare and Pulse Hi tech businesses 15 Consistent and healthy growth across business verticals Pathology Revenue (Rs Cr)* Pathology Vials (Lakhs)* 142.8 YoY% YoY% 125.4 127.6 57.2 +27% +19% 112.5 112.2 51.4 52.5 48.1 46.4 71.6 71.0 65.6 56.3 60.1 +26% 25.8 26.6 +29% 22.9 22.6 20.6 10.1 11.2 10.2 11.5 11.8 1.6 1.8 1.7 2.0 2.1 +17% +29% Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 178.9 Cr 202.2 Cr 182.5 Cr 210.7 Cr 225.6 Cr +26% 70.3 76.1 70.7 80.3 85.9 +22% Lakhs Lakhs Lakhs Lakhs Lakhs *Above numbers do not include Tanzania business 16 Strong and consistent growth outlined by key metrics Tests performed (Mn)^ Patients (Mn) Quarterly active franchisees (#) +28% +17% +23% 55.2 43.1 4.6 11,730 9,551 34.7 8,145 Q1FY25 Q1FY26 Q1FY27 Q1FY25 Q1FY26 Q1FY27 Q1FY25 Q1FY26 Q1FY27 Revenue per test (INR) *^ Revenue per patient (INR) Tests per patient (#)^ -2% +7% +9% 10.2 404 9.3 40.3 40.5 39.8 Q1FY25 Q1FY26 Q1FY27 Q1FY25 Q1FY26 Q1FY27 Q1FY25 Q1FY26 Q1FY27 * Excludes material and others revenue ^Definition of test conducted revised from Q1 FY27 to exclude calculated parameters. Restated numbers from previous quarters: -FY26 Q1 –43.1 Mn, Q2 –48.4 Mn, Q3 –44.5 Mn, Q4 –52.7 Mn -FY25 Q1 –34.7 [Showing first 8,000 characters — download PDF for full document]